A year after the US Department of Justice announced it would give credit to companies that voluntarily self-disclose misconduct, biopharmaceutical companies remain uncertain about when they should initiate conversations with the agency and what they should share.
When Should Companies Self-Disclose Potential Misconduct To DOJ?
Former DOJ official notes this can be a difficult question before government initiates an investigation unless there is an obvious problem. DOJ official describes benefits of cooperation and how data analytics have changed the way the department identifies and vets cases.
